Earnings & Results
Roche Confirms Mid-Single-Digit Sales Growth Guidance for 2026 After CHF 46.5 Billion Nine-Month Sales
By News Desk ·
Key takeaways
- Roche confirmed its fiscal year 2026 guidance for mid-single-digit group sales growth and high-single-digit core earnings per share growth at constant exchange rates.
- Roche reported CHF 46.5 billion in group sales for the first nine months of 2026, up 6% at constant exchange rates and 1% in Swiss francs.
- Third-quarter sales rose 7% at constant exchange rates and 8% in Swiss francs, with pharmaceuticals up 7% and diagnostics up 4%.
Roche Holding AG confirmed its fiscal year 2026 earnings guidance on October 22, 2026, expecting group sales to grow in the mid single digit range at constant exchange rates and core earnings per share to grow in the high single digit range. MarketScreener published the confirmation.
Roche's Nine-Month Sales and Third-Quarter Growth
EuropaWire reported that Roche recorded CHF 46.5 billion in group sales for the first nine months of 2026, an increase of 6% at constant exchange rates and 1% in Swiss francs. Third-quarter sales rose 7% at constant exchange rates and 8% in Swiss francs, with pharmaceuticals up 7% and diagnostics up 4%. Roche reaffirmed its 2026 outlook, expecting mid-single-digit sales growth and high-single-digit core earnings per share growth.
Roche is a Swiss pharmaceutical and diagnostics company that develops prescription medicines and companion diagnostic tests across oncology, neurology, immunology, ophthalmology and infectious diseases, serving patients in more than 100 countries through over 90,000 employees and three autonomous research and development engines, pRED, gRED/Genentech and Chugai, according to company records. The company was founded in 1896 and is headquartered in Basel, Switzerland.
Roche's Pipeline and Investment Commitments
According to akta.pro company records, Roche signed a global collaboration with Nurix Therapeutics on June 8, 2026, to co-develop and co-commercialize bexobrutideg (NX-5948), an oral BTK degrader for B-cell malignancies and autoimmune indications, with $700 million upfront, up to $2.3 billion in milestones and a 50/50 US profit split. The same records show Roche confirmed it will not pull its previously announced €600 million investment for a diagnostic production site in Penzberg, Germany.
Roche's Recent Trial and Licensing News
Reuters reported on October 21, 2026, that Roche's experimental multiple sclerosis pill fenebrutinib reduced the annualized relapse rate by 55% versus teriflunomide in relapsing MS patients over 96 weeks in late-stage trials, and cut slowly expanding lesions by up to 30% and paramagnetic rim lesions by 62%. Longevity.Technology reported the same day that Rona Therapeutics granted Roche worldwide rights to an ALK7-silencing RNAi drug targeting visceral fat, with up to $100 million in upfront and near-term milestones plus up to $1.06 billion in development, regulatory and commercial milestones.
What Comes Next for Roche
In Vivo reported that Roche expects approvals of giredestrant in breast cancer and fenebrutinib in multiple sclerosis to boost 2027 growth. Roche projects CHF 67.4 billion in revenue and CHF 17.2 billion in earnings by 2029, according to akta.pro company records.